Stereotactic body radiotherapy using a radiobiology-based regimen for stage i nonsmall cell lung cancer: A multicenter study

Cancer

Volumn 118, Issue 8, 2012, Pages 2078-2084

  Shibamoto, Yuta ^a   Hashizume, Chisa ^b   Baba, Fumiya ^a   Ayakawa, Shiho ^c   Manabe, Yoshihiko ^a   Nagai, Aiko ^a   Miyakawa, Akifumi ^a   Murai, Taro ^a   Iwata, Hiromitsu ^a   Mori, Yoshimasa ^b   Mimura, Mikio ^c   Ishikura, Satoshi ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b Nagoya Kyoritu Hospital   (Japan)

^c NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

Author keywords

dose; fractionation; lung cancer; reoxygenation; stage I; stereotactic body radiotherapy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER STAGING; CAUSE SPECIFIC SURVIVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTANT METASTASIS; ESOPHAGITIS; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION DOSE; RADIATION PNEUMONIA; RIB FRACTURE; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL RATE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIOBIOLOGY; RADIOSURGERY; RADIOTHERAPY DOSAGE;

EID: 84859641143     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26470     Document Type: Article

References (29)

1. Uematsu M, Shioda A, Suda A, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small-cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 2001; 51: 666-670.
2. Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007; 2 (suppl 3): S94-S100.
3. Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009; 27: 3290-3296.
4. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010; 303: 1070-1076.
5. Haasbeek CJA, Lagerwaard FJ, Antonisse ME, Slotman BJ, Senan S,. Stage I nonsmall cell lung cancer in patients aged >75 years. Outcomes after stereotactic radiotherapy. Cancer 2010; 116: 406-414.
6. Nagata Y, Hiraoka M, Mizowaki T, et al. Survey of stereotactic body radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group. Int J Radiat Oncol Biol Phys 2009; 75: 343-347.
7. Chang JY, Balter PA, Dong LD, et al. Stereotactic body radiation therapy in ventrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008; 72: 967-971.
8. Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early stage non-small-cell lung carcinoma: 4-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009; 75: 677-682.
9. Guckenberger M, Wulf J, Mueller G, et al. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys 2009; 74: 47-54.
10. Nagata Y, Hiraoka M, Shibata T, et al. A phase II trial of stereotactic body radiation therapy for operable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group (JCOG0403) [abstract]. Int J Radiat Oncol Biol Phys 2010; 78 (suppl): S27-S28.
11. Durand RE,. Cell cycle kinetics in an in vitro tumor model. Cell Tissue Kinet 1976; 9: 403-412.
12. Shibamoto Y, Yukawa Y, Tsutsui K, Takahashi M, Abe M,. Variation in the hypoxic fraction among mouse tumors of different types, sizes, and sites. Jpn J Cancer Res 1986; 77: 908-915.
13. Kallman RF, Rockwell S,. Effects of radiation on animal tumor models. In:, Adams GE, Kallman RF, eds. Cancer: A Comprehensive Treatise. Volume 6. New York: Plenum Press; 1977: 225-279.
14. Shibamoto Y, Kitakabu Y, Murata R, et al. Reoxygenation in the SCCVII tumor after KU-2285 sensitization plus single or fractionated irradiation. Int J Radiat Oncol Biol Phys 1994; 29: 583-586.
15. Murata R, Shibamoto Y, Sasai K, et al. Reoxygenation after single irradiation in rodent tumors of different types and sizes. Int J Radiat Oncol Biol Phys 1996; 34: 859-865.
16. Timmermann R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early stage lung cancer. J Clin Oncol 2006; 24: 4833-4839.
17. Baba F, Shibamoto Y, Tomita N, et al. Stereotactic body radiotherapy for stage I lung cancer and small lung metastasis: evaluation of an immobilization system for suppression of respiratory tumor movement and preliminary results [serial online]. Radiat Oncol 2009; 4: 15.
18. Iwata H, Shibamoto Y, Hashizume C, et al. Hypofractionated stereotactic body radiotherapy for primary and metastatic liver tumors using the Novalis image-guided system: preliminary results regarding efficacy and toxicity. Technol Cancer Res Treat 2010; 9: 619-627.
19. Koto M, Takai Y, Ogawa Y, et al. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. Radiother Oncol 2007; 85: 429-434.
20. Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery [published online ahead of print July 15, 2010]? Int J Radiat Oncol Biol Phys 2010.
21. Matsuo Y, Shibuya K, Nagata Y, et al. Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011; 79: 1104-1111.
22. Onimaru R, Fujino M, Yamazaki K, et al. Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy. Int J Radiat Oncol Biol Phys 2009; 70: 374-381.
23. Takeda A, Sanuki N, Kunieda E, et al. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in 5 fractions to the periphery of the planning target volume calculated using a superposition algorithm. Int J Radiat Oncol Biol Phys 2009; 73: 442-448.
24. Brown JM, Diehn M, Loo BW,. Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys 2010; 78: 323-327.
25. Willner J, Baier K, Caragiani E, Tschammler A, Flentje M,. Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 52: 382-389.
26. Qiao X, Tullgren O, Lax I, Sirzen F, Lewensohn R,. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer 2003; 41: 1-11.
27. Kestin LL, Grills IS, Guckenberger M, et al. Substantial dose-response relationship with clinical outcome for lung stereotactic body radiotherapy (SBRT) delivered via online image guidance [abstract]. Int J Radiat Oncol Biol Phys 2010; 78 (suppl): S14.
28. Withers HR, Taylor JMG, Maciejewski B,. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988; 27: 131-146.
29. Petersen C, Eicheler W, Frommel A, et al. Proliferation and micromilieu during fractionated irradiation of human FaDu squamous cell carcinoma in nude mice. Int J Radiat Biol 2003; 79: 469-477.